Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s share price gapped down prior to trading on Monday . The stock had previously closed at $49.0192, but opened at $39.92. Zealand Pharma A/S shares last traded at $38.75, with a volume of 9,921 shares traded.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zealand Pharma A/S currently has an average rating of “Moderate Buy”.

Get Zealand Pharma A/S alerts:

Get Our Latest Report on Zealand Pharma A/S

Zealand Pharma A/S Price Performance

The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $48.10 and its 200 day simple moving average is $59.39. The firm has a market capitalization of $2.76 billion, a P/E ratio of 2.86 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Sell-side analysts forecast that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Recommended Stories

• Five stocks we like better than Zealand Pharma A/S
• Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look
• 3 Energy Stocks Built for the AI Power Boom—And Beyond
• Allstate’s Comeback Is Turning Into a Profit Machine
• What’s Make of Macy’s: Berkshire Hathaway’s Latest Buy

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.